Related Experiment Video
Updated: Jun 27, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Autoimmune hepatitis. Part B: diagnosis
1Mayo Clinic, 200 First Street S.W, Rochester, Minnesota 55905, USA. czaja.albert@mayo.edu
Insights
Autoimmune hepatitis diagnosis relies on codified criteria and scoring systems, as it lacks a definitive cause or test. Treatment decisions for autoimmune hepatitis should focus on disease severity, not symptoms.
Area of Science:
- Hepatology
- Immunology
- Internal Medicine
Background:
- Autoimmune hepatitis (AIH) diagnosis lacks a definitive etiologic agent and diagnostic test.
- Diagnostic criteria have been codified by the International Autoimmune Hepatitis Group, including a scoring system.
- Early forms of AIH may present as centrilobular (zone 3) necrosis, potentially transforming into interface hepatitis.
Purpose of the Study:
- To review the diagnostic challenges and evolving understanding of autoimmune hepatitis.
- To highlight the importance of objective disease severity in treatment decisions for AIH.
- To discuss emerging autoantibodies and genetic associations in autoimmune hepatitis.
Main Methods:
- Review of codified diagnostic criteria and scoring systems for autoimmune hepatitis.
- Analysis of clinical presentations, including acute, severe, and fulminant forms.
- Examination of ethnic variations, concurrent autoimmune diseases, and genetic associations (HLA types).
Main Results:
- The absence of a definitive diagnostic test can lead to missed or misapplied AIH diagnoses.
- Centrilobular necrosis can be an early sign of AIH, evolving into interface hepatitis.
- Asymptomatic AIH patients often become symptomatic; treatment should be based on severity, not symptoms.
Conclusions:
- Autoimmune hepatitis diagnosis requires careful application of codified criteria and scoring systems.
- Treatment decisions for AIH must prioritize objective disease severity over symptom presence.
- Emerging autoantibodies and HLA associations offer prognostic insights and aid in understanding AIH phenotypes.
Abstract:
Diagnostic criteria have been codified by the International Autoimmune Hepatitis Group, and a scoring system can quantify the strength of the diagnosis and over-ride the impact of absent or inconsistent features. The absence of a definable etiologic agent and precise diagnostic test, implies that the diagnosis may be missed or misapplied. Centrilobular (zone 3) necrosis may be an early form of autoimmune hepatitis and this pattern can transform to the classical pattern of interface hepatitis. An acute severe or fulminant presentation is possible, and different ethnic groups may have different manifestations and outcomes. Asymptomatic patients at presentation commonly become symptomatic, and treatment decisions must be based on objective features of disease severity and not the presence or absence of symptoms. Concurrent autoimmune diseases are frequent, and they may constitute an autoimmune polyglandular syndrome associated with a single gene mutation. Emerging autoantibodies of possible prognostic value are antibodies to soluble liver antigen/liver pancreas, asialoglycoprotein receptor, actin, and liver cytosol type 1. HLA DRB1*03, *04, *03-*04, *07, *13 and DQB1*02 are associated with the occurrence, clinical phenotype and outcome of autoimmune hepatitis. Variant syndromes should be suspected if cholestatic features are prominent and conventional treatment is ineffective.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction
01:28Graves' Disease I: Introduction
01:23Cirrhosis I: Introduction
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:12Type I Diabetes I: Introduction